BiotechTube
DefEYE

DefEYE

Boston, United States· Est.
defeye.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DefEYE is an emerging player in the ophthalmic medical device sector, specializing in decellularized biologic matrices. The company's core innovation is its BIOVANCE 3L Ocular product, which is positioned as the only decellularized basement membrane (DBM) available for ocular surface reconstruction, featuring room-temperature storage and multiple size options. Led by CEO Rob Sambursky, MD, DefEYE aims to transform therapeutic approaches in eye care by providing integrated solutions that improve surgical outcomes and manage ocular surface diseases. The company is in the commercial stage with its first product, targeting a significant market opportunity in corneal and conjunctival repair.

OphthalmologyOcular Surface Disease

Technology Platform

Decellularized Basement Membrane (DBM) matrices with a proprietary triple-layer architecture designed for ocular tissue repair and regeneration.

Opportunities

The aging population and rising incidence of ocular surface diseases create a large and growing market.
The practical benefits of room-temperature storage and a triple-layer design offer a strong value proposition to surgeons and surgical centers over traditional cryopreserved grafts.
The platform technology allows for potential expansion into adjacent ophthalmic surgical applications.

Risk Factors

Facing entrenched competition from established amniotic membrane products.
As a private, early-commercial company, it is dependent on external funding and must successfully execute its sales strategy to achieve profitability.
Long-term clinical data for the specific product is still being accumulated.

Competitive Landscape

DefEYE competes in the biologic ocular graft market, primarily against providers of amniotic membrane allografts (e.g., Bio-Tissue, Inc., Katena Products, Inc., TissueTech, Inc.). Its key differentiators are the triple-layer structure of its decellularized basement membrane and room-temperature storage, which it positions against the more common cryopreserved amniotic membranes.

More companies in Regenerative Medicine →More companies in United States →